The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A Phase 1, Randomized, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of MEDI4212 in Allergic Subjects
- collapse (OSKIRA-Asia-1X): A Long-term Study to Assess the Safety of Fostamatinib in the Treatment of Rheumatoid Arthritis in Asia
- collapse A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Tolerability of MEDI-557, a Humanized Monoclonal Antibody with an Extended Half-Life Against Respiratory Syncytial Virus (RSV), Administered to Healthy Adults
- collapse A Phase 1/2 Randomized, Dose-Finding Study of MEDI-551 in Subjects with Relapsing-Remitting Multiple Sclerosis
- collapse A Study to Evaluate Biomarkers in Blood and Synovial Fluid in Subjects with Rheumatoid Arthritis
- collapse A Phase 2B, Randomized, Double-Blind Study to Evaluate the Efficacy of Tralokinumab in Adults with Uncontrolled, Severe Asthma
- collapse A Phase 2B, Dose-Ranging Study to Evaluate the Efficacy and Safety of Sifalimumab in Adults with Systemic Lupus Erythematosus
- collapse A Phase 2B, Dose-Ranging Study to Evaluate the Efficacy and Safety of MEDI-563 in Adults with Uncontrolled Asthma
- collapse A Phase 2A, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of MEDI-563 in Subjects with Moderate-to-Severe COPD and Sputum Eosinophilia
- collapse A randomised, parallel-group, open-label, multicentre, 3-month phase IV, efficacy and tolerability study of budesonide/formoterol (Symbicort® Turbuhaler® 160/4.5μg/inhalation, 2 inhalations twice daily) added to tiotropium (SpirivaTM 18 μg/inhalation, 1 inhalation once daily) compared with tiotropium (SpirivaTM18 μg/inhalation, 1 inhalation once daily) alone in severe chronic obstructive pulmonary disease (COPD) patients
